www.fdanews.com/articles/145867-avastin-touted-over-long-term-for-nsclc
Avastin Touted Over Long Term for NSCLC
April 24, 2012
Carefully selected patients with non-small cell lung cancer (NSCLC) achieved a median overall survival of 31 months with first-line chemotherapy with bevacizumab, followed by long-term bevacizumab maintenance.
MedPage Today
MedPage Today